Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 5/20 | 0.50 |
| ▸ | SCN1A | P35498 | 10/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | MTR | Q99707 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104473 | 0.89 | SSTR5 (0.48) | SSTR5SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL3095201 | 0.87 | SCN1A (0.52) | SSTR5SCN1ASCN5ASCN9AMTR | |
| SCHEMBL3086964 | 0.86 | SCN1A (0.50) | SSTR5SCN1ASCN5ASCN9AMTR | |
| SCHEMBL3633362 | 0.85 | SSTR5 (0.52) | SSTR5KCNH2SSTR3 | |
| SCHEMBL3876136 | 0.77 | SSTR5 (0.58) | SSTR5KCNH2SSTR3 | |
| SCHEMBL3090041 | 0.76 | SCN1A (0.50) | SSTR5SCN1ASCN5ASCN9A | |
| SCHEMBL6191353 | 0.75 | MTR (0.66) | SCN1ASCN5ASCN9AMTR | |
| SCHEMBL9762133 | 0.74 | SCN1A (0.67) | SCN1ASCN5ASCN9AMTR | |
| SCHEMBL31633166 | 0.72 | MTR (0.44) | SCN1ASCN5ASCN9AMTR | |
| SCHEMBL9761779 | 0.72 | TSHR (0.58) | SCN1ASCN5ASCN9AMTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | claimed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | claimed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | claimed |
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885SCN1A 1682/4885SCN5A 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.